 |
 |
The cannabinoid receptor antagonist SR141716A reduces L-dopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease Cannabinoid receptor antagonism reduces levodopa-induced dyskinesias in marmosets without affecting the antiparkinson effect of levodopa, according to this report. In an adjunct experiment in reserpine-treated rats, administration of SR141716A reduced D1 agonist-induced locomotion, and increased D2 agonist-induced locomotion, in a dose-dependent manner. The authors suggest "Overactivation of the endocannabinoid modulation of the direct pathway may play a part in the generation of levodopa-induced dyskinesia," and suggest that cannabinoid receptors may be beneficial in dyskinesia treatment. M Hill, D Peggs, AR Crossman, JM Brotchie P-MO-119 Parkinsonism and Related Disorders, Volume 5 Supplement, 1999 <http://www.wemove.org> janet paterson 52 now / 41 dx / 37 onset snail-mail: PO Box 171 Almonte Ontario K0A 1A0 Canada website: a new voice <http://www.geocities.com/SoHo/Village/6263/> e-mail: <[log in to unmask]>